Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ERN1 | O75460 | 9/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | PI4KA | P42356 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7229501 | 0.81 | CYP2A6 (0.42) | MAPTNPC1RAB9AERN1KDM4E | |
| SCHEMBL6503392 | 0.79 | MAPT (0.49) | TLR4TLR2MAPTNPC1RAB9A | |
| SCHEMBL3031212 | 0.79 | MAPT (0.63) | TLR4TLR2MAPTNPC1RAB9A | |
| SCHEMBL6974757 | 0.79 | AURKB (0.50) | TLR4TLR2MAPTNPC1RAB9A | |
| SCHEMBL12643379 | 0.79 | MAPT (0.69) | TLR4TLR2MAPTNPC1RAB9A | |
| SCHEMBL8302605 | 0.79 | MAPT (0.62) | TLR4TLR2MAPTNPC1RAB9A | |
| SCHEMBL14714243 | 0.79 | MAPT (0.53) | MAPTERN1KDM4EPOLB | |
| SCHEMBL5381509 | 0.79 | CRHBP (0.54) | MAPTERN1KDM4EPOLB | |
| SCHEMBL7229673 | 0.78 | ERN1 (0.46) | MAPTNPC1RAB9AERN1KDM4E | |
| SCHEMBL13736898 | 0.77 | MAPT (0.49) | TLR4TLR2MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3159337-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | Ventirx Pharmaceuticals, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| EP-2467380-B1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS INC (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160137608-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-9242964-B2 | Substituted benzoazepines as toll-like receptor modulators | VENTIRX PHARMACEUTICALS, INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20140142086-A1 | Substituted Benzoazepines as Toll-Like Receptor Modulators | ARRAY BIOPHARMA, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-8524702-B2 | Substituted benzoazepines as toll-like receptor modulators | VENTIRX PHARMACEUTICALS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| CN-102781933-A | Substituted benzazepines as modulators of TOLL-like receptors | VENTIRX PHARMACEUTICALS INC | 2012-11-14 | — | — | CN | disclosed |
| EP-2467380-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | Ventirx Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-20110118235-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2011022509-A2 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | VENTIRX PHARMACEUTICALS, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137608-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | TLR8, TLR1, TLR7 | TLR4 4/4885TLR2 7/4885MAPT 4097/4885 |
| US-20110118235-A1 | SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | TLR8, TLR1, TLR7 | TLR4 4/4885TLR2 7/4885MAPT 4097/4885 |
| US-20140142086-A1 | Substituted Benzoazepines as Toll-Like Receptor Modulators | TLR8, TLR1, TLR7 | TLR4 4/4885TLR2 7/4885MAPT 4097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.